Objetivo: Descrever a implantação de um serviço de telemedicina de UTI durante a pandemia de COVID-19, assim como descrever e analisar os resultados dos primeiros quatro meses de funcionamento do programa. Métodos: Estudo observacional descritivo da implantação de um serviço de telemedicina de UTI seguido de análise retrospectiva dos dados clínicos de pacientes com COVID-19 internados em UTI entre abril e julho de 2020. Resultados: O serviço foi implantado em quatro semanas e mostrou-se viável em meio à pandemia. O treinamento foi desenhado para ser remoto e baseado em evidências, promovendo a padronização do atendimento aos pacientes com COVID-19. Mais de 100.000 visualizações foram registradas nas plataformas on-line de acesso livre e no aplicativo móvel. Durante o período do estudo, os casos de 326 pacientes com COVID-19 foram avaliados no programa. A mediana de idade foi de 60 anos (variação: 49-68 anos). Houve predomínio do sexo masculino (56%) e alta prevalência de hipertensão arterial (49,1%) e diabetes mellitus (38,4%). Na admissão na UTI, 83,7% dos pacientes estavam em ventilação mecânica invasiva, com uma mediana da relação PaO 2 /FiO 2 < 150. Ventilação pulmonar protetora foi possível em 75% dos casos. A mortalidade na UTI foi de 65%, e a mortalidade hospitalar foi de 68%. Conclusões: A telemedicina de UTI forneceu treinamento multidisciplinar aos profissionais de saúde e acompanhamento clínico de centenas de pacientes críticos. A iniciativa na rede pública foi pioneira e mostrou-se viável em meio à pandemia de COVID-19, incentivando a criação de projetos semelhantes que combinem práticas baseadas em evidências, treinamento e telemedicina. Descritores: Telemedicina; Cuidados críticos; Infecções por coronavírus; Administração dos cuidados ao paciente.
Economic losses caused by enzootic bovine leukosis (EBL) have been of interest since World War II, when the neoplastic form of EBL increased dramatically in Europe. Olson (1974) and House et al. (1975) showed that animals with lymphosarcoma caused by the bovine leukosis virus (BLV) had reduced milk yields, a less efficient reproductive performance and high veterinary costs and mortality rates, while many carcasses were rejected at slaughter. However, the actual impact of BLV infection in cattle without lymphosarcoma is not clear. The purpose of the study reported here was to compare some productive and reproductive responses of cattle that were antibody-positive (BLVj) or negative (BLVk) for BLV.Holstein dairy cows in commercial dairy farms were used in this study. Blood samples were collected and subjected to BLV serological examination by the agar gel immunodiffusion test of Miller & van der Maaten (1976). Animals were then grouped as BLVj or BLVk according to their serological response to the BLV antigen. Productive and reproductive histories were obtained from individual animal records and the following factors were considered : milk production, calving interval and birth rate. For milk production, we had the daily milk yields of 547 animals, and for calving interval the time between two successive parturitions for 444 cows. These values were examined by ANOVA and when this was significant a Student's t test was carried out for each age group. Birth rates, the percentage of animals that calved in 1 year, were available for 557 animals and were examined with the Z-two proportion test. For all analyses, P 0n05 was considered significant. Mean daily milk yield was lower by 11 % in BLVj than in BLVk cattle (19n4 v. 21n8 kg ; Table 1) and this was significant or approached significance for some age groups. This agrees with the findings of Reinhardt et al. (1988) and Brenner et al. (1989), who found decreases in milk yield of 3 and 3n5 % respectively. However, Langston et al. (1978), Huber et al. (1981) and Burridge et al. (1982) found no differences in the milk production of BLVj and BLVk cattle.No differences were found in the reproductive characteristics investigated (calving interval and birth rate ; see Tables 2 and 3). These results agree with the observations of previous workers (Langston et al. 1978 ; Huber et al. 1981 ; Brenner
Gastrointestinal helminthic infection is an important worldwide sheep disease. The emergence of anthelminthic resistance has led to drives to seek new means of therapeutic control of helminthiasis in sheep. Several data demonstrated the adjuvant effect of Propionibacterium acnes on resistance to infection. Herein, we evaluate the adjuvant effect of the commercial suspension containing LPS and P. acnes on experimental helminthiasis. Sheep received three doses of LPS and P. acnes commercial suspension or saline 0.9% (control group). Both groups received orally Haemonchus contortus infective larvae on day 0. Parasitological, haematological, lymphoproliferation analysis, IL-5 and IgE determination were made once a week until 35th day after infection. Our results revealed increase on packed cell volumes on day 14, in LPS + P. acnes treated group. On 21st and 35th days after infection in the same group occurred increase on circulating eosinophils and lymphocytes, and also in the lymphoproliferative response to mitogen. On 35th day, the faecal eggs peak in LPS + P. acnes treated group was significantly lower than control. A negative correlation between faecal eggs counts and circulating eosinophils in the immunostimulant treated group was also observed. Our findings suggest that LPS + P. acnes suspension can be used as a strategy to control helminthiasis in sheep.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.